SCHEMBL26554698

SCHEMBL26554698

CC(C)(C)OC(=O)N1CC[C@H](CNc2nc3cc(Br)ccc3o2)C1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.54
TDO2 P48775 1/20 0.54
USP30 Q70CQ3 3/20 0.45
JAK2 O60674 1/20 0.43
JAK3 P52333 1/20 0.43
PTK2 Q05397 1/20 0.43
CCNT1 O60563 1/20 0.42
CDK9 P50750 1/20 0.42
KDM4E B2RXH2 1/20 0.42
PKM P14618 1/20 0.42
CETP P11597 2/20 0.41
IRAK1 P51617 1/20 0.41
FPR2 P25090 2/20 0.41
FPR3 P25089 1/20 0.41
ACKR3 P25106 1/20 0.40
BRD3 Q15059 1/20 0.40
BCDIN3D Q7Z5W3 1/20 0.40
GPR119 Q8TDV5 1/20 0.40
PTGES O14684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26554699 1.00 IDO1 (0.54) IDO1TDO2USP30JAK2JAK3
SCHEMBL26185530 0.94 KDM4E (0.48) IDO1TDO2USP30KDM4EPKM
SCHEMBL31267602 0.93 IDO1 (0.54) IDO1TDO2USP30JAK2JAK3
SCHEMBL25401409 0.85 USP30 (0.43) IDO1TDO2USP30PTGES
SCHEMBL25398239 0.85 USP30 (0.43) IDO1TDO2USP30PTGES
SCHEMBL25398234 0.85 USP30 (0.43) IDO1TDO2USP30PTGES
SCHEMBL29437084 0.85 USP30 (0.53) IDO1TDO2USP30FPR2FPR3
SCHEMBL26554295 0.85 USP30 (0.53) IDO1TDO2USP30FPR2FPR3
SCHEMBL29437097 0.85 USP30 (0.53) IDO1TDO2USP30FPR2FPR3
SCHEMBL26554290 0.85 USP30 (0.53) IDO1TDO2USP30FPR2FPR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230331683-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. 2023-10-19 US disclosed
US-20230331683-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. 2023-10-19 US disclosed
EP-4211111-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY University of Virginia Patent Foundation (US) 2023-07-19 EP disclosed
WO-2022056045-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2022-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331683-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY SPNS2, SPCS2, SMN1; SMN2 IDO1 3979/4885TDO2 2986/4885USP30 2419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.